Comparative Pharmacology
Head-to-head clinical analysis: LOW OGESTREL 21 versus QUASENSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW OGESTREL 21 versus QUASENSE.
LOW-OGESTREL-21 vs QUASENSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
100 mg orally every 12 hours.
None Documented
None Documented
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive